2,650 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by BayBridge Capital Group LLC

BayBridge Capital Group LLC bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,650 shares of the pharmaceutical company's stock, valued at approximately $1,149,000. Vertex Pharmaceuticals makes up about 1.1% of BayBridge Capital Group LLC's investment portfolio, making the stock its 23rd largest holding.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Arlington Trust Co LLC increased its stake in Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 33 shares during the period. Fortitude Family Office LLC acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $30,000. Baystate Wealth Management LLC grew its position in Vertex Pharmaceuticals by 49.0% in the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company's stock valued at $31,000 after buying an additional 25 shares during the last quarter. Quest Partners LLC purchased a new position in Vertex Pharmaceuticals during the 4th quarter worth $33,000. Finally, NBC Securities Inc. acquired a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth $34,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the sale, the executive vice president now owns 55,804 shares in the company, valued at $23,755,762.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Trading Up 0.7 %

Shares of NASDAQ:VRTX traded up $3.27 during trading on Thursday, reaching $450.80. The stock had a trading volume of 1,554,711 shares, compared to its average volume of 1,216,625. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $320.01 and a fifty-two week high of $453.71. The business has a fifty day moving average price of $412.50 and a 200-day moving average price of $406.09. The stock has a market cap of $116.33 billion, a P/E ratio of 29.25, a PEG ratio of 2.26 and a beta of 0.39. The company has a quick ratio of 3.29, a current ratio of 3.50 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.66 by $1.10. Vertex Pharmaceuticals had a return on equity of 23.08% and a net margin of 39.46%. The business had revenue of $2.69 billion for the quarter, compared to analysts' expectations of $2.58 billion. During the same quarter last year, the firm earned $2.67 earnings per share. The business's revenue was up 13.3% on a year-over-year basis. As a group, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Royal Bank of Canada increased their price target on shares of Vertex Pharmaceuticals from $417.00 to $424.00 and gave the stock a "sector perform" rating in a report on Tuesday, May 7th. Wells Fargo & Company increased their price objective on Vertex Pharmaceuticals from $500.00 to $540.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 6th. Maxim Group lowered shares of Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Wednesday, January 31st. Sanford C. Bernstein downgraded shares of Vertex Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Friday, February 2nd. Finally, Oppenheimer reiterated an "outperform" rating and issued a $500.00 price objective on shares of Vertex Pharmaceuticals in a research note on Monday, April 15th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $432.18.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.